• Presentation of the positive topline results from the pivotal Phase 3 ARES trial evaluating MaaT013 in patients with acute Graft-versus-Host Disease (GI-aGvHD), marking a milestone as the first global Phase 3 trial of a microbiome-based therapy in hemato-oncology. 
• Analysis of the ARES trial outcomes, highlighting MaaT013’s unprecedented efficacy as a third-line treatment for GI-aGvHD and its potential to reshape therapeutic approaches in this high-need patient population.
• Potential of microbiome-based therapies in hemato-oncology

MaaT Pharma’s representative